Abstract
Clozapine (1-10 mg/kg s.c.) produces a selective increase in dopamine release in rat prefrontal cortex which is, in large part (approximately 50%), mediated via activation of 5-HT1A receptors. Clozapine is a moderately potent, partial 5-HT1A receptor agonist and activation of 5-HT1A receptors may contribute to its efficacy against negative symptoms and reduced extrapyramidal side effect liability. Agonist affinity for 5-HT1A receptors could thus be a desirable feature in the design of new antipsychotics.
MeSH terms
-
Animals
-
Antipsychotic Agents / administration & dosage
-
Antipsychotic Agents / pharmacology*
-
Clozapine / administration & dosage
-
Clozapine / pharmacology*
-
Dopamine / metabolism*
-
Dose-Response Relationship, Drug
-
Injections, Subcutaneous
-
Male
-
Prefrontal Cortex / drug effects
-
Prefrontal Cortex / metabolism*
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Serotonin / drug effects
-
Receptors, Serotonin / metabolism*
-
Serotonin Receptor Agonists / pharmacology*
Substances
-
Antipsychotic Agents
-
Receptors, Serotonin
-
Serotonin Receptor Agonists
-
Clozapine
-
Dopamine